ArticleAnnals of hematology2026
Incidence, clinical features and risk factors of interstitial pneumonia in children with acute lymphoblastic leukemia.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Interstitial pneumonia (IP) is an important pulmonary complication in children with acute lymphoblastic leukemia (ALL), yet its incidence, clinical characteristics, and predictors remain insufficiently defined. We conducted a single-center retrospective study including 484 children diagnosed with ALL and treated at the First Affiliated Hospital of Sun Yat-sen University between February 2002 and January 2022. Among 484 patients, 33 (6.82%) developed IP. The incidence was higher in boys than girls (8.92% vs. 2.94%) and significantly elevated in high-risk versus non–high-risk ALL (16.67% vs. 3.78%, P < 0.001). IP occurred more frequently during maintenance therapy than intensive chemotherapy (75.75% vs. 24.25%, P = 0.047), with a median onset of 122 days after maintenance initiation. Common symptoms included dyspnea (100%), fever (87.87%), and cough (75.75%). Imaging commonly demonstrated diffuse ground-glass opacities and interstitial changes. Management involved antibacterial therapy (84.84%), antifungals (75.75%), antivirals (72.72%), corticosteroids (87.87%), and oxygen therapy (93.93%). Twenty-six patients improved, whereas seven died, predominantly due to respiratory failure. In high-risk patients during maintenance therapy, lower absolute lymphocyte counts and changes in absolute neutrophil count/white blood cell ratio (ANC/WBC) and absolute lymphocyte count/white blood cell ratio (ALC/WBC) were significantly associated with IP onset, suggesting their potential predictive value. No variables were significantly associated with mortality. Early recognition and timely initiation of corticosteroids and supportive care are essential. Hematologic indices may help identify children at heightened risk, supporting improved surveillance and risk-adapted management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.